Compare IDR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | DCTH |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 578.4M |
| IPO Year | 2000 | 2015 |
| Metric | IDR | DCTH |
|---|---|---|
| Price | $31.18 | $16.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 205.7K | ★ 673.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 70.15 | ★ 107.53 |
| EPS | ★ 0.63 | 0.04 |
| Revenue | ★ $42,406,253.00 | N/A |
| Revenue This Year | $25.52 | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $50.70 | $418.25 |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $22.31 | $8.12 |
| 52 Week High | $54.70 | $17.42 |
| Indicator | IDR | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 69.91 |
| Support Level | $27.46 | $10.16 |
| Resistance Level | $41.05 | N/A |
| Average True Range (ATR) | 1.82 | 0.79 |
| MACD | 0.23 | 0.37 |
| Stochastic Oscillator | 41.09 | 88.85 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.